Torrent Pharmaceuticals Morgan Bond
TORNTPHARM | 3,350 17.50 0.53% |
As of now, Torrent Pharmaceuticals' Long Term Debt is increasing as compared to previous years. The Torrent Pharmaceuticals' current Long Term Debt Total is estimated to increase to about 31.8 B, while Short and Long Term Debt Total is projected to decrease to under 27.1 B. With a high degree of financial leverage come high-interest payments, which usually reduce Torrent Pharmaceuticals' Earnings Per Share (EPS).
The current Total Current Liabilities is estimated to decrease to about 29.4 B. The current Liabilities And Stockholders Equity is estimated to decrease to about 81.8 BTorrent |
Given the importance of Torrent Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Torrent Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Torrent Pharmaceuticals Limited to issue bonds at a reasonable cost.
Popular Name | Torrent Pharmaceuticals Morgan Stanley 3971 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | INE685A01028 |
Bond Issue ISIN Code | US61744YAL20 |
S&P Rating | Others |
Maturity Date | 22nd of July 2038 |
Issuance Date | 24th of July 2017 |
Coupon | 3.971 % |
Torrent Pharmaceuticals Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning Torrent Pharmaceuticals Use of Financial Leverage
Understanding the composition and structure of Torrent Pharmaceuticals' debt gives an idea of how risky is the capital structure of the business and if it is worth investing in it. The degree of Torrent Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 40.2 B | 27.1 B | |
Net Debt | 31.9 B | 22.3 B | |
Short Term Debt | 23.5 B | 15.5 B | |
Long Term Debt | 16 B | 27.5 B | |
Short and Long Term Debt | 23.3 B | 16.9 B | |
Long Term Debt Total | 29.3 B | 31.8 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Torrent Stock
Torrent Pharmaceuticals financial ratios help investors to determine whether Torrent Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Torrent with respect to the benefits of owning Torrent Pharmaceuticals security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.